The second generation of BCR-ABL tyrosine kinase inhibitors.

Abstract excerpt

Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML). Because of the excellent hematologic and cytogenetic responses, imatinib has moved toward first-line treatment for newly diagnosed CML. However, the emergence of resistance to imatinib remains a major problem in the treatment of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Allosteric Regulation
• Share to Drug Design
• Share to Fusion Proteins, bcr-abl